These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

828 related articles for article (PubMed ID: 18243663)

  • 1. World Psychiatric Association Pharmacopsychiatry Section statement on comparative effectiveness of antipsychotics in the treatment of schizophrenia.
    Tandon R; Belmaker RH; Gattaz WF; Lopez-Ibor JJ; Okasha A; Singh B; Stein DJ; Olie JP; Fleischhacker WW; Moeller HJ;
    Schizophr Res; 2008 Mar; 100(1-3):20-38. PubMed ID: 18243663
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effectiveness of second-generation antipsychotics in patients with treatment-resistant schizophrenia: a review and meta-analysis of randomized trials.
    Chakos M; Lieberman J; Hoffman E; Bradford D; Sheitman B
    Am J Psychiatry; 2001 Apr; 158(4):518-26. PubMed ID: 11282684
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antipsychotics in the treatment of schizophrenia: an overview.
    Tandon R
    J Clin Psychiatry; 2011; 72 Suppl 1():4-8. PubMed ID: 22217436
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of antipsychotic treatment on tardive dyskinesia: a 6-month evaluation of patients from the European Schizophrenia Outpatient Health Outcomes (SOHO) Study.
    Tenback DE; van Harten PN; Slooff CJ; Belger MA; van Os J;
    J Clin Psychiatry; 2005 Sep; 66(9):1130-3. PubMed ID: 16187770
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Aripiprazole in schizophrenia and schizoaffective disorder: A review.
    Stip E; Tourjman V
    Clin Ther; 2010; 32 Suppl 1():S3-20. PubMed ID: 20152550
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antipsychotic treatment of schizophrenia: an update.
    Bruijnzeel D; Suryadevara U; Tandon R
    Asian J Psychiatr; 2014 Oct; 11():3-7. PubMed ID: 25216917
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Using antipsychotic agents in older patients.
    Alexopoulos GS; Streim J; Carpenter D; Docherty JP;
    J Clin Psychiatry; 2004; 65 Suppl 2():5-99; discussion 100-102; quiz 103-4. PubMed ID: 14994733
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antipsychotic safety and efficacy concerns.
    Meyer JM
    J Clin Psychiatry; 2007; 68 Suppl 14():20-6. PubMed ID: 18284274
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Second generation antipsychotics for schizophrenia.
    Feltus MS; Gardner DM
    Can J Clin Pharmacol; 1999; 6(4):187-95. PubMed ID: 10601752
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative efficacy of antipsychotics in the treatment of schizophrenia: a critical assessment.
    Tandon R; Fleischhacker WW
    Schizophr Res; 2005 Nov; 79(2-3):145-55. PubMed ID: 16139989
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness of second-generation antipsychotics and perphenazine in a randomized trial of treatment for chronic schizophrenia.
    Rosenheck RA; Leslie DL; Sindelar J; Miller EA; Lin H; Stroup TS; McEvoy J; Davis SM; Keefe RS; Swartz M; Perkins DO; Hsiao JK; Lieberman J;
    Am J Psychiatry; 2006 Dec; 163(12):2080-9. PubMed ID: 17151158
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antipsychotics in adults with schizophrenia: comparative effectiveness of first-generation versus second-generation medications: a systematic review and meta-analysis.
    Hartling L; Abou-Setta AM; Dursun S; Mousavi SS; Pasichnyk D; Newton AS
    Ann Intern Med; 2012 Oct; 157(7):498-511. PubMed ID: 22893011
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of newer generation antipsychotics in the treatment of schizophrenia.
    Tandon R; Jibson MD
    Psychoneuroendocrinology; 2003 Jan; 28 Suppl 1():9-26. PubMed ID: 12504069
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Short-term efficacy and safety of lurasidone in the treatment of schizophrenia].
    Samalin L; Ben Gharbia M; Garnier M; Llorca PM
    Encephale; 2014 Dec; 40(6):507-17. PubMed ID: 25453735
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lurasidone in the treatment of schizophrenia: a critical evaluation.
    Bruijnzeel D; Yazdanpanah M; Suryadevara U; Tandon R
    Expert Opin Pharmacother; 2015; 16(10):1559-65. PubMed ID: 26111577
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An analysis of the effect of funding source in randomized clinical trials of second generation antipsychotics for the treatment of schizophrenia.
    Montgomery JH; Byerly M; Carmody T; Li B; Miller DR; Varghese F; Holland R
    Control Clin Trials; 2004 Dec; 25(6):598-612. PubMed ID: 15588746
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment pathway and patterns of clozapine prescribing for schizophrenia in New Zealand.
    Wheeler AJ
    Ann Pharmacother; 2008 Jun; 42(6):852-60. PubMed ID: 18477732
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Randomized controlled trial of the effect on Quality of Life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1).
    Jones PB; Barnes TR; Davies L; Dunn G; Lloyd H; Hayhurst KP; Murray RM; Markwick A; Lewis SW
    Arch Gen Psychiatry; 2006 Oct; 63(10):1079-87. PubMed ID: 17015810
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oral antipsychotics for the treatment of schizophrenia: heterogeneity in efficacy and tolerability should drive decision-making.
    Volavka J; Citrome L
    Expert Opin Pharmacother; 2009 Aug; 10(12):1917-28. PubMed ID: 19558339
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Upcoming agents for the treatment of schizophrenia: mechanism of action, efficacy and tolerability.
    Bishara D; Taylor D
    Drugs; 2008; 68(16):2269-92. PubMed ID: 18973393
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 42.